• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Sen. Lankford says claims that GOP ‘weaponizing hunger’ over SNAP is ‘painful spin’: Full interview

admin - Latest News - November 9, 2025
admin
18 views 23 secs 0 Comments



In an exclusive interview with Meet the Press, Sen. James Lankford (R-Okla.) pushed back against Democrats’ claims that Republicans are ‘weaponizing hunger’ by withholding SNAP funding, and called on the party to ‘just fix the problem’ by voting to reopen the government.



Source link

TAGS:
PREVIOUS
Nov. 9, 2025, 9:00 AM ESTBy Juhi Doshi“Wicked: For Good” director Jon M. Chu has built his career on turning stories about outsiders into celebrations of belonging. But in an interview with “Meet the Press” that aired Sunday, the filmmaker opened up about following his own yellow brick road: one marked by rejection and resilience.“My whole life, I’ve been trying to prove myself, that I can be here, that I can be in this business,” Chu told “Meet the Press” moderator Kristen Welker. “And I think I was always searching for that kind of validation. But through the process of making movies and doing it over — and I had a whole long career before ever doing ‘Wicked’ — I think I got killed many times.”“Wicked: For Good,” the second chapter in his adaptation of the hit Broadway musical, will hit theaters on Nov. 21. It is loosely based on Gregory Maguire’s 1995 novel — a creative reimagining of “The Wizard of Oz.” The new film is produced by Universal Pictures, part of NBCUniversal.“Wicked,” which Chu also directed, is the most profitable Broadway film adaptation of all time and was nominated for 10 Oscars, of which it won two.Chu says he found that lesson of authenticity reflected in his film’s two main characters — Elphaba and Glinda — and in the actors who played them, Cynthia Erivo and Ariana Grande.Glinda, played by Grande, and Elphaba, played by Erivo, form an unlikely friendship, each challenging the other to view life from a new perspective and defy the expectations their world pins onto them.“I learned so much from Elphaba and Glinda and from Cynthia and Ariana,” he said. “I think I’ve gotten to let go of that idea of proving yourself.”When Chu was just 23, fresh out of the University of Southern California’s film school, he landed two movie deals. Both collapsed before production began.“There were days where I was like, ‘Am I a fool?’ … I would go into USC — they asked me to speak at USC, because this is the guy that just came out of college and got his deal … and I sit in the loading dock, and I’m watching all these kids excited about making a movie. And I feel like nothing. I feel like — and I just started to weep. It was probably the first time I cried in 20 years or something at that point. I was like, ‘These people think I’m a complete fake.’”Years later, after gaining experience and completing a variety of film projects such as “Step Up 2” and “Now You See Me 2,” Chu found a story that changed the trajectory of his career and became a watershed moment for Asian American representation on screen: “Crazy Rich Asians.”“‘Crazy Rich Asians’ was great, because it cracked the door open or showed a path for the other people who needed to invest money in this. I’m not sure if it was for us,” he said. “I think it was for everyone else to say, ‘Oh, these actors have value.’”“Crazy Rich Asians” was the first major Hollywood studio film to feature a majority-Asian cast in 25 years and was the highest-grossing romantic comedy of the decade. Chu says he sees his film as an “avenue” for other Asian American filmmakers to share aspects of their own experience: “Let’s own our stories and tell every version of our story we could.”However, Chu said that more representation “takes time.”“I think we have to be careful to expect too big of a change too quickly,” he said. “Of course we want that, but to change culture, it takes time. You cannot force people to do that.”Chu also says he remains deeply committed to the movie theater experience, despite the growth of streaming.“I think movies are one of our last analog spaces. It’s a space that we have to protect,” Chu said. “You have to make a choice to go in. You have to leave your phone … and then you have to just sit back in the dark and watch something for two hours through someone else’s perspective. That is maybe one of the last spaces we have to do that. It is a part of our culture.”And that, he says, is what “Wicked” is all about.“Even though it’s a fantasy, even though it’s a fairy tale, it’s our access into a human experience. What does it feel like when you believe so deeply, when you love so deeply, when you sacrifice everything? That we still have the capacity to do that,” Chu said. “It’s what my parents taught me. It’s what America has taught me.”Juhi DoshiJuhi Doshi is an associate producer with NBC News’ “Meet the Press.”
NEXT
Hakeem Jeffries says ‘I hope’ shutdown ends before Thanksgiving: Full interview
Related Post
November 11, 2025
ByHeart recalls infant formula sold nationwide due to serious health risks
October 31, 2025
Prince Andrew stripped of royal titles amid mounting pressure
September 27, 2025
Sept. 27, 2025, 5:30 AM EDTBy Berkeley Lovelace Jr.For people who rely on certain prescription drugs, including weight loss, asthma and cancer medications, President Donald Trump’s post announcing 100% tariffs on foreign brand-name drugs offers little clarity on when — or if — medications might see price hikes. “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump said on Truth Social late Thursday. “‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”Experts say Trump’s post raises a lot of questions. Here are five major ones. What drugs will be impacted?Trump’s post doesn’t specify whether brand-name drugmakers with an existing U.S. plant would be exempt, whether that exemption would include all their products, or whether it would only be for the drugs manufactured at the U.S. site. Novo Nordisk and Eli Lilly, makers of the weight loss drugs Wegovy and Zepound, respectively, have announced plans to invest in U.S. manufacturing. But it’s unclear if their intent to invest will warrant an exemption. On Tuesday, Lilly announced plans for a $6.5 billion manufacturing facility in Houston that will produce Zepbound and its other GLP-1 drug, Mounjaro, following a recent commitment to build a $5 billion plant near Richmond, Virginia. Novo Nordisk, a Danish company, said in June it would spend $4.1 billion to construct a second GLP-1 fill-finish plant in Clayton, North Carolina.AstraZeneca, which makes the asthma drug Symbicort, also announced in July that it will invest $50 billion over the next five years to expand its research and development and manufacturing footprint in the U.S. Many other popular brand-name drugs, however, are primarily manufactured overseas, particularly in Europe, said Rena Conti, an associate professor at Boston University’s Questrom School of Business.Botox, made by Allergen, and the cancer drug Keytruda from drugmaker Merck are made in Ireland. (Keytruda’s manufacturing has increasingly moved to the United States in recent years, but it’s not clear if that would earn an exemption from Trump’s tariffs.)Others, including some for blood and lung cancers, as well as vaccines, are made in places like India and China, Conti said. “I think what’s most at risk here are branded products that come from China and India,” she said. The E.U. and Japan already have trade agreements in place that cover pharmaceuticals, she added, and it’s unclear whether the new tariff will supersede that. Will patients see prices increase?Only 1 in 10 of the prescriptions filled in the U.S. are for brand-name drugs; the vast majority are for generics, which are much cheaper and will not be affected by these tariffs. Whether patients see price increases will depend on how many drugmakers receive exemptions — and on whether companies choose to pass those costs on to patients at the pharmacy counter, said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. ​​“Ultimately, tariffs are taxes on patients,” Kesselheim said, “and to the extent that drug companies see increases in cost due to tariffs, they will pass those costs on to patients.”Some companies may decide not to pass the costs along. So far, the 15% tariffs on imports from the E.U. haven’t translated into big price hikes for U.S. patients, Conti noted. To be sure, a 100% tariff would be far more costly for a company. Price hikes may not start right away, as drugmakers find out whether they qualify for an exemption. There also might be a lag since U.S. law prevents drugmakers from increasing the price of drugs faster than inflation.“What if you’re doing updates to the plant you currently have? What if you’re planning a facility? Do those count?” Kesselheim said. “It’s all very ambiguous.”Some patients may not notice additional price hikes at all, given how costly brand-name drugs already are in the U.S., said Arthur Caplan, the head of the Division of Medical Ethics at NYU Langone Medical Center in New York City. “I can certainly predict that some patients will immediately feel price increases that will shock them on some of these drugs,” Caplan said.Could insurers absorb the costs?Insurers and middlemen, known as pharmacy benefit managers, could try to negotiate drugmakers or absorb some of the tariff-related costs, Caplan said.It’s more likely, however, that they’d pass it on to patients in the short term, potentially in the form of a larger copay, he said.It’s not only patients with private insurance that should be worried about price hikes, Kesselheim said. Those who get their drugs covered through government health programs could also see price increases.“The government is the largest purchaser of prescription drugs in the market, through Medicare, Medicaid and the VA, so it’s really the government or government payers that are going to see the largest impact on price increases,” he said. Will tariffs spur more U.S. drug manufacturing?It’s unlikely, Kesselheim said. The decision to build a plant “is a complicated and expensive one” that requires several regulatory hurdles and years of planning.Conti noted that by the time new manufacturing plants are completed, Trump would likely be out of office.“It is somewhere between two years and five years to get new production facilities built,” she said, “and it can be in the millions of dollars depending on whether the product that you’re making is a small molecule drug or a biologic.”Even putting money back into an existing plant isn’t quick.“If you want to switch a line or retool a factory to make a product, then we’re talking about somewhere between 18 to 36 months to do that,” Conti said, “because you have to show the U.S. regulator that you can make it at this factory at scale, and the product is what it says it is, or is high quality and meets the quality standards of the U.S.”In a statement, Alex Schriver, a spokesperson for the trade group the Pharmaceutical Research and Manufacturers of America, said “most innovative medicines prescribed in America are already made in America” and companies continue to invest in the U.S.“Tariffs risk those plans because every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures,” Schriver said. “Medicines have historically been exempt from tariffs because they raise costs and could lead to shortages.”What about shortages?If Trump keeps his focus solely on brand-name drugs, U.S. patients are unlikely to face shortages, Kesselheim said.“Their profits are just so, so far beyond this tariff cost that they could probably be OK or raise the prices of the drugs,” he said. “They would probably not stop production as a result.”But that excludes, he added, some smaller companies who may make niche brand-name products and may not have the resources to take on the extra costs. If tariffs extend to generics, the risk is far greater, Caplan added. Unlike brand-name drugs, generic drugs are typically sold at close to the cost they’re made, he said, which makes it difficult for companies to justify the cost of building a new facility. They’d likely be forced to walk away from production or close their plants altogether.Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
November 7, 2025
The view from an Israeli outpost in Gaza
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved